Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
Study Suggests Biomarker For Resistance to Tamoxifen
Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
Patients Who Smoke In Treatment Do Worse Than Those Who Quit
Dendritic Cell Vaccine May Boost Median Survival
Decline In Breast Cancer May Be Related to Drop In HT
Triple-Negative Breast Cancer Increases With Number of Births
PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
Statins Associated With Lower Risk Of High-Grade Prostate Cancer
Mentholated Cigarettes Cause No More Lung Cancer, Deaths
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves BMS’s Yervoy For Metastatic Melanoma
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
